Sarepta says early filing for DMD gene therapy may be back onThe development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the Share XSarepta says early filing for DMD gene therapy may be back onhttps://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-may-be-back-on/
Bayer trumpets $1bn CRISPR deal with Mammoth BioBayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed Share XBayer trumpets $1bn CRISPR deal with Mammoth Biohttps://pharmaphorum.com/news/bayer-trumpets-crispr-deal-mammoth-bio/
After trial win, Novartis nabs COVID drug from Molecular PartnersThere are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around Share XAfter trial win, Novartis nabs COVID drug from Molecular Partnershttps://pharmaphorum.com/news/after-trial-win-novartis-nabs-covid-drug-from-molecular-partners/
Another big AI deal as Sanofi taps Exscientia for 15 new drugsIf the last couple of days is an indication, 2022 is already shaping up to be the year Share XAnother big AI deal as Sanofi taps Exscientia for 15 new drugshttps://pharmaphorum.com/news/another-big-ai-deal-as-sanofi-taps-exscientia-for-15-new-drugs/
AstraZeneca goes bigger in amyloidosis with Neurimmune dealAstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, Share XAstraZeneca goes bigger in amyloidosis with Neurimmune dealhttps://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/
Amgen pledges $1.9bn to alliance with AI specialist GenerateFresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has Share XAmgen pledges $1.9bn to alliance with AI specialist Generatehttps://pharmaphorum.com/news/amgen-pledges-1-9bn-to-alliance-with-ai-specialist-generate/
Otsuka dips its toe in psychedelic waters, backing Mindset PharmaDespite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary Share XOtsuka dips its toe in psychedelic waters, backing Mindset Pharmahttps://pharmaphorum.com/news/otsuka-dips-its-toe-in-psychedelic-waters-backing-mindset-pharma/
PureTech challenges Roche’s Esbriet in head-to-head IPF trialRoche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, Share XPureTech challenges Roche’s Esbriet in head-to-head IPF trialhttps://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/
Look out GSK, Pfizer and BioNTech are coming for ShingrixGlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Share XLook out GSK, Pfizer and BioNTech are coming for Shingrixhttps://pharmaphorum.com/news/look-out-gsk-pfizer-and-biontech-are-coming-for-shingrix/
Gritstone bio trumpets first data for ‘multivariant’ COVID jabA COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone Share XGritstone bio trumpets first data for ‘multivariant’ COVID jabhttps://pharmaphorum.com/news/gritstone-bio-trumpets-first-data-for-multivariant-covid-jab/
Biogen looks beyond Spinraza in SMA with Ionis dealSpinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with Share XBiogen looks beyond Spinraza in SMA with Ionis dealhttps://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/
Boehringer’s spesolimab data raises hope for serious skin diseaseFresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim’s spesolimab has shown encouraging efficacy in Share XBoehringer’s spesolimab data raises hope for serious skin diseasehttps://pharmaphorum.com/news/boehringers-spesolimab-data-raises-hope-for-serious-skin-disease/
Novartis adds gene therapy for blindness with Gyroscope buyGyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a Share XNovartis adds gene therapy for blindness with Gyroscope buyhttps://pharmaphorum.com/news/novartis-adds-gene-therapy-for-geographic-atrophy-with-gyroscope-buy/
Blow for Novartis as ligelizumab can’t top Xolair in phase 3Novartis’ big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XBlow for Novartis as ligelizumab can’t top Xolair in phase 3https://pharmaphorum.com/news/blow-for-novartis-as-ligelizumab-cant-top-xolair-in-phase-3/
Ipsen places €480m bet on Genfit’s liver drug elafibranorGenfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis Share XIpsen places €480m bet on Genfit’s liver drug elafibranorhttps://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/
Mesoblast pummelled as Novartis exits COVID dealNovartis as opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a Share XMesoblast pummelled as Novartis exits COVID dealhttps://pharmaphorum.com/news/mesoblast-pummelled-as-novartis-exits-covid-deal/
Flush with COVID cash, Pfizer tables $6.7bn bid for ArenaPfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing Share XFlush with COVID cash, Pfizer tables $6.7bn bid for Arenahttps://pharmaphorum.com/news/flush-with-covid-cash-pfizer-tables-6-7bn-bid-for-arena/
UCB chases after Argenx with FcRN drug for myasthenia gravisUCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor Share XUCB chases after Argenx with FcRN drug for myasthenia gravishttps://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/
